The EMEA Liquid Biopsy Market was valued at USD 280 million in 2022 and is projected to grow at a CAGR of around 13.98% during the forecast period, i.e., 2023-28. This comprehensive market research report has been recently released by Markntel Advisors, a prominent firm specializing in research, consulting, and data analytics, offering an extensive array of strategic reports across various industry sectors. The report systematically examines numerous factors that have significantly shaped the market dynamics in recent years.
EMEA Liquid Biopsy Market Driver:
Cancer has been a chronic disease over the past years & would continue to ascend in the forecasting year as well, owing to the increasingly sedentary lifestyle, smoking, and drinking habit of the individual, which would require better diagnostic facilities, treatment, and care for the patients. The continuous boost in the number of cancer patients emphasizes the need for accurate & convenient diagnostic systems for early cancer detection. Consequently, with the rising number of cancer patients, especially across Turkey, France, Denmark, etc., the usage of Liquid Biopsy is also uplifting. The advantages of liquid biopsy, like lower cost, early prognosis, therapy monitoring, etc., have further enhanced their adoption over conventional diagnostic methods to detect urothelial carcinoma, non-urological cancers, and other blood cancers.
The use of liquid biopsy has also been upscale to determine the best treatments for cancer patients, especially lung & prostate cancer, in which the patient receives specific targeted drugs. Hence, the improved investments by government organizations & pharmaceutical companies to escalate the research & development of new cancer treatments are anticipated to augment the growth of the EMEA Liquid Biopsy Market during the forecasted period.
Request for a sample copy of this report: https://www.marknteladvisors.com/query/request-sample/emea-liquid-biopsy-market.html
How Has the EMEA Liquid Biopsy Market Been Divided?
In the report, we have conducted a thorough analysis of the market by breaking it down into various high-performing segments. We aim to clarify the factors that contribute to the success and increased market share of each segment. This analysis includes an examination of their significant impact on the EMEA Liquid Biopsy market in terms of sales, expansion opportunities, job creation, and other vital factors. These components are categorized as follows:
Based on Product and Services
– Assay Kits
Based on Circulating Biomarker
– Circulating Tumour Cell (CTC)
– Circulating Tumour DNA (ctDNA)
– Cell Free DNA (cfDNA)
– Extracellular Vesicle (EVS)
Based on Technology
– Multi gene analysis by Next Generation Sequencing (NGS)
– Single gene analysis by Polymer chase reaction (PCR)
Based on Sample Type
– Others (Cerebrospinal Fluid, Plasma, Saliva, etc.)
Based on Application
– Cancer Application
— Lung Cancer
— Breast Cancer
— Colorectal Cancer
— Prostate Cancer
— Melanoma cancer
— Others (Pancreatic, Liver, etc.)
– Non Cancer Application
— Non Invasive Parental Testing
— Organ Transplantation
— Infectious Diseases
– Clinical Application
— Early Cancer Screening
— Therapy Selection
— Treatment Monitoring
— Recurrence Monitoring
Based on End User
– Hospital and Physician laboratories
– Reference Laboratories
– Academic & Research Centre
Full Market Research Report – https://www.marknteladvisors.com/research-library/emea-liquid-biopsy-market.html
The report highlights Geographical
– The UK
– Saudi Arabia
– The UAE
– South Africa
– Rest of Europe Middle East & Africa
where the EMEA Liquid Biopsy market is active to varying degrees. We place special emphasis on regions that have a predominant presence in the market, underlining their geographical significance in the context of the EMEA Liquid Biopsy market.
In the EMEA Liquid Biopsy Market, prominent companies such Thermofisher Scientific, Hoffmann La Roche Ltd, Sysmex Corporation, Qiagen N.V., Guardant Health, Bio Rad, Neo Genomics, Epigenomics, Menarini Silicon Biosystems, Agena Bioscience Inc., Silicon Biosystems, Pathway Genomics Corporation, Others (Myraid Genetics, Illumina Inc.,etc) are subject to thorough evaluation. Each company within this industry undergoes scrutiny based on the value of their products, their capabilities, and other noteworthy attributes. Additionally, this study encompasses various mergers and acquisitions, as well as recent product launches by these firms, aimed at acquainting stakeholders with the prevailing market dynamics.
Some of the Key Questions Answered in this Report:
- What are the growth projections for the years 2023-2028?
- Which market factors will aid in developing client and business strategies?
- What are the critical market opportunities for each segment enlisted in the research report?
- What are the primary growth tactics used by the major market players?
Why You Should Choose MarkNtel Advisors for Your Market Research Needs:
Valuable Insights for Informed Decisions: Our reports offer valuable and current insights that can be easily turned into actions. Whether you’re a company looking to launch a new venture or expand profitably, our reports will guide you towards success.
Numerous Benefits: Our analysis of the EMEA Liquid Biopsy Market provides a wide range of advantages, including market research insights, comprehensive information, industry projections, and data trends.
In-Depth Analysis: Our EMEA Liquid Biopsy Market report goes deep into various industries, expertly examining important market trends, consumer behavior, and competitive landscapes. Stakeholders can expect a wealth of insights to shape their business strategies.
Our approach facilitates the identification of rapidly expanding companies within the industry, scrutinizing their profound impact on the EMEA Liquid Biopsy market in terms of sales, expansion, employment opportunities, and other pivotal aspects. Additionally, the report places particular emphasis on key components such as the regions where the market demonstrates varying levels of activity, with a specific focus on geographically dominant areas.
Ask Analyst for Customization and Browse full report with TOC List of Figure: https://www.marknteladvisors.com/query/request-customization/emea-liquid-biopsy-market.html
About us –MarkNtel Advisors is a leading research, consulting, & data analytics firm that provides an extensive range of strategic reports on diverse industry verticals. We deliver data to a substantial & varied client base, including multinational corporations, financial institutions, governments, & individuals, among others.
Our specialization in niche industries & emerging geographies allows our clients to formulate their strategies in a much more informed way and entail parameters like Go-to-Market (GTM), product development, feasibility analysis, project scoping, market segmentation, competitive benchmarking, market sizing & forecasting, & trend analysis, among others, for 15 diverse industrial verticals.
Using such information, our clients can identify attractive investment opportunities & strategize their moves to yield higher ROI (Return of Interest) through an early mover advantage with top-management approaches.
We understand the mounting & diverse needs of our clients. Hence, our analysts focus on emerging industries to provide services that fulfill their assessment of the current & future industry potential, identify white spaces & hotspots, & venture into new geographies or business segments in the future.
Contact Us –
Call: 📞 +1 628 895 8081, +91 120 4278433
Email: 📧 firstname.lastname@example.org
Visit to know more: 🌐 https://www.marknteladvisors.com/